Researchers at Syracuse University have identified a brain peptide, TDN, that effectively curbs appetite and enhances glucose control in lab animals without causing nausea or vomiting. This innovative approach targets brain support cells, offering a potential ‘shortcut’ to weight loss by bypassing the neuron-focused pathways that trigger adverse side effects. Human clinical trials are anticipated to commence around 2026-2027. This groundbreaking discovery may revolutionize obesity treatment by providing a safer and more tolerable alternative to traditional weight-loss drugs.